New drug ABBV-706 made available for some lung cancer patients before approval
NCT ID NCT07310277
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides early access to the investigational drug ABBV-706 for people with small cell lung cancer who have no other treatment options and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is given by intravenous infusion.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABBV-706 (intravenous infusion)
What this could lead to
If this drug shows benefit, it could offer a new treatment option for patients with small cell lung cancer who have no other suitable therapies.
What could go wrong
This is an expanded access program, not a formal trial, so evidence is limited. The drug is investigational and may not work or could cause side effects. Availability depends on location and eligibility.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••